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Abstract
Rationale: Due to the invasive nature of the procedures involved, most studies of Mycobacterium tuberculosis (Mtb)-specific
immunity in humans have focused on the periphery rather than the site of active infection, the lung. Recently, antigens
associated with Mtb-latency and -dormancy have been described using peripheral blood (PB) cells; however their response
in the lung is unknown. The objective of this report was to evaluate, in patients prospectively enrolled with suspected active
tuberculosis (TB), whether the latency antigen Rv2628 induces local-specific immune response in bronchoalveolar lavage
(BAL) cells compared to PB cells.
Material/Methods: Among the 41 subjects enrolled, 20 resulted with active TB. Among the 21 without active disease, 9
were defined as subjects with latent TB-infection (LTBI) [Quantiferon TB Gold In-tube positive]. Cytokine responses to
Rv2628 were evaluated by enzyme linked immunospot (ELISPOT) assay and flow cytometric (FACS) analysis. RD1-secreted
antigen stimulation was used as control.
Results: There was a significantly higher frequency of Rv2628- and RD1-specific CD4
+ T-cells in the BAL of active TB patients
than in PB. However the trend of the response to Rv2628 in subjects with LTBI was higher than in active TB in both PB and
BAL, although this difference was not significant. In active TB, Rv2628 and RD1 induced a cytokine-response profile mainly
consisting of interferon (IFN)-c-single-positive over double-IFN-c/interleukin (IL)-2 T-cells in both PB and BAL. Finally, BAL-
specific CD4
+ T-cells were mostly effector memory (EM), while peripheral T-cell phenotypes were distributed among naı ¨ve,
central memory and terminally differentiated effector memory T-cells.
Conclusions: In this observational study, we show that there is a high frequency of specific T-cells for Mtb-latency and RD1-
secreted antigens (mostly IFN-c-single-positive specific T-cells with an EM phenotype) in the BAL of active TB patients. These
data may be important for better understanding the pathogenesis of TB in the lung.
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Introduction
Tuberculosis (TB) is commonly thought to have a simple binary
distribution, active disease and latent infection. Although latent
TB infection (LTBI) is generally associated with bacterial
containment in some inactive form in the granuloma [1], the
current definition of LTBI includes a diverse range of individuals,
from those who have completely cleared, to those who are
incubating actively replicating bacteria in the absence of clinical
symptoms [2,3]. On the other side, active TB in humans and non-
primate animals is characterized by diverse pathological presen-
tations, ranging from sterile tissue to caseous hypoxic lesions
containing variable numbers of bacteria, to liquefied cavities with
a massive load of replicating organisms [2,4]. Based on this, M.
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continuous spectrum ranging from sterilizing immunity, to
subclinical active disease, to fulminant active disease with
conventional designations of LTBI, and active disease correspond-
ing to partially overlapping regions of biological heterogeneity
[4,5].
Due to the invasive nature of the procedures involved, most
studies of Mtb-specific immunity in humans have focused on
peripheral blood (PB) rather than the site of active infection, the
lung [1,6–9]. However, tissue-specific mucosal immunity in the
lung, as measured e.g. in bronchoalveolar lavage (BAL), may differ
significantly from the periphery and may yield more relevant clues
about the mechanisms and immune components of protection and
disease.
During LTBI, the tubercle bacilli contained within granulomas
[1] are thought to be subjected to nutrient and oxygen deprivation
[10,11]. As part of the Mtb-adaptive response to hypoxia,
expression of the DosR regulon is observed. The functions of
most DosR-regulon-encoded proteins, hereafter referred to as
latency antigens, are still mostly unknown [12,13]. Recently, we
described that interferon (IFN)-c responses to Mtb latency antigens
Rv2628c [14] are associated with LTBI and that within the CD4
+
T-cells the response to Rv3133c, Rv1733c and Rv2029c is mainly
associated with cytokine mono-functional expression [15-18]. It
would be important to evaluate the immune response to these
antigens at the site of TB because as reported above, not all lesions
in the human lung are active during the disease [4,5]. Thus these
latency antigen-specific T-cells may be present in the TB-affected
lung in association with silent lesions, but this has not been
evaluated yet.
Based on the expression of surface markers associated with cell
maturation [19], CD4
+ T-cells can be phenotypically divided into
at least four different populations: naı ¨ve (N) defined as CD62L
+,
CD45R0
-, central memory (CM) defined as CD62L
+, CD45R0
+,
effector memory (EM) defined as CD62L
-, CD45R0
+ and
terminally differentiated effector memory T-cells (EF) defined as
CD62L
-, CD45R0
-. In several infection models including TB, it
has been shown that effector T-cells are expanded during active
replication, whereas only memory cells are detectable after control
or eradication [20-22]. However, no characterization of the
phenotype of Mtb-specific cells during active disease simultaneous-
ly evaluated in blood and BAL has been performed yet.
It has recently been shown that the response to RD1 [early
secreted antigenic target (ESAT)-6 and culture filtrate protein
(CFP)-10] in BAL is associated with active TB [23–25]. However,
no characterization of the surface cell profile associated with cell
maturation after specific-Mtb stimulation has been performed
until now.
Millington et al. have shown a predominant profile of IFN-c-
secreting T-cells in the PB of active TB patients, whereas
interleukin (IL)-2-secreting cells appear in patients after successful
treatment and may be considered as a consequence of central
memory T-cells expansion, caused by the reduced Mtb antigen
load [26]. Similarly Biselli et al have shown that IL-2 secretion is
associated to LTBI after long-term stimulation with RD1 antigens
[27]. All together, these data indicate that the concomitant
evaluation of IFN-c and IL-2 may be instrumental in assessing the
different stages of TB.
Therefore, we prospectively enrolled patients with a high
suspect of active TB who were undergoing BAL, and used the
enzyme-linked immunospot test (ELISPOT) to investigate whether
the latency antigen Rv2628 induces local-specific immune
response at the site of infection. Responses to RD1 antigens were
evaluated as control [23,28]. Furthermore, we analyzed the
cytokines (IFN-c and IL-2) produced and the phenotype of
responding cells after specific antigen stimulation by flow
cytometry (FACS).
Results
Characteristics of the population
Forty-one subjects with suspected active pulmonary TB disease,
who had negative results in acid fast bacilli (AFB) smears from
sputa, and who had consequently undergone BAL procedure for
diagnostic purposes were enrolled. After enrollment, the diagnosis
was microbiologically confirmed in 10 and based on clinical
criteria in 10. Among the 21 subjects without active TB, 9 were
defined as LTBI because they tested positive to QuantiFERON
TB Gold-In tube (QFT-IT) (Cellestis Limited, Carnegie, Victoria,
Australia). Demographic characteristics, Bacillus Calmette et
Gue ´rin (BCG) vaccination status, QFT-IT results and final
diagnosis are reported in Table 1.
Comparison of Rv2628- and RD1-induced cytokines
responses in circulating and BAL lymphocytes by
ELISPOT
In vitro analyses could be performed in most, but not all BAL
samples, due to cell constraints or due to being scored as
indeterminate or anergic (Table 2). Regarding the 12 patients with
lung diseases other than TB, although the majority was analyzable
(Table 2), no response to Rv2628 or RD1 was detected (data not
shown) and therefore these data were not included in the analysis
reported below.
We first used ELISPOT to analyze the response to Rv2628- and
RD1-antigens in active TB and LTBI subjects separately,
comparing BAL cells (BALC) and peripheral blood mononuclear
cells (PBMC) responses.
In the 16 patients with active TB who were tested, we observed
a significantly higher number of IFN-c-producing T-cells in
response to both Rv2628 (BALC median: 24 spot forming cells
(SFC)/10
6 cells, interquartile range (IQR): 4–148 SFC/10
6 cells;
PBMC median: 0 SFC/10
6 cells, IQR: 0–8 SFC/10
6 cells) and
RD1 antigens (BALC median: 140 SFC/10
6 cells, IQR: 4–442
SFC/10
6 cells; PBMC median: 30 SFC/10
6 cells, IQR: 10–70
SFC/10
6 cells) (p=0.006 and p=0.007, respectively) in BALC
than in PBMC (Figure 1 A, B).
It was previously shown that compared to those with pulmonary
TB, a low number of LTBI subjects had a sufficient number of
BALC to perform a comparative analysis of both compartments.
This is likely due to lower local cell activation and consequent
recruitment in the lung [24]. Here we confirmed this data (table 2).
Therefore, in the 7 subjects where the comparative analysis was
possible, no significant difference was found in terms of IFN-c-
producing T-cells of BALC compared to PBMC in response to
Rv2628- (BALC median: 41 SFC/10
6 cells, IQR: 0–42 SFC/10
6
cells; PBMC median: 41 SFC/10
6 cells, IQR: 0–43 SFC/10
6 cells)
and RD1-antigens (BALC median: 4 SFC/10
6 cells, IQR: 0–124
SFC/10
6 cells; PBMC median: 112 SFC/10
6 cells, IQR: 44–136
SFC/10
6 cells), (p=0.8 and p=0.6, respectively) (Figure 1 C, D).
To better characterize the response to Rv2628- and RD1-
antigens, we evaluated the magnitude of response to these antigens
in PBMC and BALC separately. The trend of the response to
Rv2628 in subjects with LTBI was higher than in active TB in
both PB and BAL, although this difference was not significant. In
PBMC, the RD1 frequency was significantly higher than Rv2628
in both active TB (p=0.009) and LTBI subjects (p=0.03)
(Figure 2A). Differently, in BALC (Figure 2B) the frequency of
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those with active TB (p=0.004).
As previously shown for the RD1-secreted antigens [23,24],
these results show a significantly higher frequency of Mtb-specific
responses to Rv2628 at the site of TB disease than at the periphery
in patients with active TB. The magnitude of the response to RD1
is significantly higher than what reported for the antigen of
latency. Moreover, the trend of the response to Rv2628 in subjects
with LTBI is higher than in active TB in both PB and BAL,
although this difference is not significant.
Comparison of Rv2628- and RD1-induced cytokine
responses in PB and BAL by FACS analysis
We analyzed separately the response to Rv2628- and RD1-
antigens in active TB and LTBI subjects in PB and BALC by
FACS analysis.
FACS analysis was performed simultaneously in 14 patients to
evaluate T-cell multiple cytokine production (IFN-c and/or IL-2).
Among them, in line with results from the ELISPOT assay, we
found a significantly higher number of multiple cytokine
producing CD4
+ T-cells in response to Rv2628 (BALC median:
0.14%, IQR: 0.04–0.90%; PB median: 0.01%, IQR: 0. –0.04%)
and RD1antigens (BALC median: 1.49%, IQR: 0.05–8.22%; PB
median: 0.04%, IQR: 0.01–0.19%) in BALC than in PB
(p=0.001 and p=0.001, respectively) (Figure 3 A, B). Regarding
the CD8
+ T-cell specific response, we detected specific T-cell
response to RD1 antigen in only one of the 14 samples evaluated,
in both PB (2.31%) and BALC (8.50%).
Regarding the LTBI subjects, among the 5 subjects where
sufficient cell numbers were available (table 2), no significant
difference was found in the CD4
+ T-cell response to Rv2628- and
RD1-antigens (data not shown). No CD8
+ T-cell response to
Rv2628- and RD1-antigens was found (data not shown).
Altogether these FACS results confirm the data generated by
ELISPOT.
Cytokine profile in response to Mtb-specific antigens in
active TB patients
To further assess the functional capacity of Mtb-specific T cells
in active TB subjects, we analyzed the proportion of each cytokine
subset contributing to the total RD1 and Rv2628 responses by
FACS.
Based on the cut-off (see MATERIALS and METHODS
section), a robust analysis of cytokine profiles and CD4
+ T-cell
phenotypes in response to Rv2628 antigens was possible in 11
BAL samples and 2 PB samples of active TB patients. We found
that the cytokine profile of response to Rv2628 was homogeneous
and predominantly consisted of IFN-c single-positive cells (PB
median: 100%, IQR: 99–100%; BALC median: 100%, IQR:
85.71–100%). Interestingly, the single IL-2- and double IFN-c/IL-
Table 1. Demographic and clinical characteristics of the subjects enrolled in the study.
Active TB No active TB Total p value
With LTBI No LTBI
N( % )
20 (48.8) 9 (22.0) 12 (29.3) 41(100.0)
Median Age (IQR) 33.5 (27.7–44.5) 46.0 (32.50–63.50) 37.5 (30.5–57.2) 36.0 (29.5–52.5) 0.185
Female gender 8 (40.0) 5 (55.6) 4 (33.3) 17 (41.5) 0.324
Origin 0.986
Eastern Europe 12 (60.0) 3 (33.3) 5 (41.7) 20 (48.8)
Western Europe 4 (20.0) 4 (44.4) 5 (41.7) 13 (31.7)
Asia 3 (15.0) 1 (11.1) - 4 (9.8)
Africa 1 (5.0) 1 (11.1) 2 (16.7) 4 (9.8)
BCG 0.915
Vaccinated 14 (70.0) 4 (44.4) 6 (50.0) 24 (58.5)
Unvaccinated 6 (30.0) 5 (55.6) 6 (50.0) 17 (41.5)
QTF-IT ,0.0001
Positive 17 (85.0) 9 (100.0) - 26 (63.4)
Negative 3 (15.0) - 12 (100.0) 15 (36.6)
TB Diagnoses NA
Microbiological 10 (50.0) - - -
Clinical 10 (50.0) - - -
Lung Diseases other than TB NA
Pneumonia - 6 (66.7) 7 (58.3) -
Bronchitis and lung infiltrates - 1 (11.1) 1 (8.3) -
Pleural effusion - 1 (11.1) 1 (8.3) -
Lung Abscess - - 1 (8.3) -
Emphysema and lung infiltrates - 1 (11.1) 2 (16.7) -
Footnotes: TB: Tuberculosis; IQR: Interquartile range; BCG: Bacillus Calmette et Gue ´rin; QTF-IT: QuantiFERON TB Gold in Tube; NA: not available.
doi:10.1371/journal.pone.0027539.t001
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0%, IQR: 0–7.69%; IFN-c/IL-2 median: 0%, IQR: 0–0.94%)
(Figure 4A).
Regarding the response to RD1-antigens, 11 BAL samples and
6 PB samples were further analyzed. We observed a homogeneous
cytokine profile that predominantly consisted of IFN-c single-
positive cells (PB median: 100%, IQR: 85.59–100%; BALC
median: 99.46%, IQR: 86.21–100%), with a smaller percentage of
single IL-2-producing cells (PB median: 0%, IQR: 0–6.07%;
BALC median: 0.18%, IQR: 0–1.39%), and double IFN-c/IL-2-
producing cells (PB median: 0%, IQR: 0–7.94%; BALC median:
0.36%, IQR: 0–12.07%) (Figure 4B).
Furthermore, we evaluated the phenotype of the total cytokine-
producing cells. EM cells constituted the main phenotypic
population in both PB (82%) and BAL samples (87%) in response
to Rv2628 antigen (p=0.56). Moreover as shown in figure 5A,
there was only a small proportion of EF cells (11%) in BAL
samples whereas other phenotypic populations were also repre-
sented in PB samples (16% EF, and 2% N).
Among the RD1 responders, the proportion of EM cells was
almost significantly higher in BALC (96%) than in PB samples
(88%) (p=0.06). Moreover, there was only a small proportion of
EF cells (4%) in BAL, whereas other phenotypic populations were
also present in PB (10% EF, 1% CM and 1% N) (Figure 5B).
Comparing the response to the different antigens in BALC, a
significantly higher number of EM cells responded to RD1 than to
Rv2628 (p=0.02) (Figure 5 A, B).
Based on the fact that only few LTBI patients showed a
response to RD1 and Rv2628 (Figure 1C, D) in BAL, antigen-
specific T-cell frequencies in LTBI patients were too low to
comparatively assess cytokine profiles or T-cell phenotypes from
PB and BALC in a robust manner. Therefore, no further FACS
analysis was performed in this group.
Altogether these FACS results indicate that in patients with
active TB, a higher proportion of EM cells respond to RD1-
secreted antigens in BAL than in PB. In addition, in the BAL, a
higher proportion of EM cells respond to RD1 than to Rv2628.
Discussion
For the first time to our knowledge, we demonstrated
compartment-related differences in the frequency and phenotypes
of specific T-cell immunity for the Mtb-latency antigen Rv2628 in
active TB patients who were prospectively enrolled with suspected
active disease. Moreover, we also characterized the effector/
memory phenotype of the BALC responding to RD1-secreted
antigens, different from studies reported ex vivo or in pleural fluid
[28–30].
In particular, in this observational study, we showed a higher
frequency of CD4
+ T-cells in BAL than in the PB of active TB
patients for a latency antigen, not only for RD1 as previously
shown [23–25]. Specifically, ELISPOT results, confirmed by
FACS analysis, show that there was a significantly higher
frequency of IFN-c-producing antigen-specific CD4
+ T-cells in
BALC than in PBMC. The frequency of response to RD1 antigens
was significantly higher than what was reported for Rv2628 in
BAL and peripheral blood. Secondly, we showed that the cytokine
profile predominantly consisted of IFN-c single-positive cells over
double IFN-c/IL-2 positive T-cells, both in PB and BALC
samples, independent of the stimulus. Consistent with previous
observations [28-30], BAL-specific CD4
+ T-cells presented
predominantly an EM phenotype, while peripheral T-cell
phenotypes were distributed among broader phenotypes (N,
CM, EM and EF). Moreover, a significantly higher proportion
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among the subjects with LTBI, the response to Rv2628 in BAL
was not significantly higher than in PB, as previously shown for
RD1 [23,24]. Altogether our data contribute to a better
understanding local immunity to Mtb in the lung.
We recently showed that the response to Rv2628-antigen in
blood is associated with protection [14]. In agreement with this
report, here we demonstrate that the trend of the response to this
antigen of latency in subjects with LTBI is always higher than in
active TB in both PB and BAL, although the difference is not
significant. Interestingly, in active TB patients we found that the
response to this antigen is also present at the site of infection and is
significantly higher than in the periphery. These data are in
agreement with those reported on HBHA [31–33], another
latency antigen, which showed that the response was significantly
higher in the lungs than in the periphery [34], where immune
suppression to this antigen is mediated by T-regulatory cells
[32–34].
Recent studies on patients with pleural TB showed that there is
a higher proportion of pleural cells (PFMC) with an EM
phenotype than other phenotypes in the periphery, both by ex
vivo analysis and after specific stimulation [30]. Moreover, a higher
proportion of poly-functional cells was found in PFMC than in
PBMC after specific in vitro stimulation and had an EM rather than
a CM phenotype [30]. On the contrary, in the present study we
found predominantly mono-functional cells (only IFN-c-producing
CD4
+ T-cells) in both BAL and PB samples from active TB
patients. The reason for our different findings may be due to the
different compartments analyzed (BALC vs PFMC).
IFN-c-release assays on lymphocytes from BAL during
mycobacterial infections have been suggested as being a potential
new diagnostic tool for active TB [23,25,28]. In this study we
confirm that RD1 responses in the BAL are associated with active
disease. For the first time we show that the response to a latency
antigen is increased in BAL than the periphery of patients with
active TB. Nevertheless, at both PBMC and BAL levels, the
response to Rv2628 tended to be higher in subjects with LTBI
than in those with active disease, in line with our previous
observations in whole blood [14]. Further studies are needed to
evaluate the diagnostic potential of this result.
Both CD4
+ and CD8
+ T-cells with double and mono-functional
response profiles to Mtb latency antigens can be detected with
substantial frequency in long-term latently infected individuals
[18]. In the present study only one patient with active TB showed
CD8
+ T-cell cytokine production in response to Mtb-specific
stimulation. No CD8
+ T-cell specific response was found in LTBI
subjects. However, only few LTBI individuals were evaluated and
they were not long-term infection controllers.
FIgure 1. Increased frequency of Rv2628- and RD1-response in BALC than PBMC in active TB, evaluated by ELISPOT. ELISPOT
evaluation of IFN-c-producing CD4
+ T-cells in circulating and BAL lymphocytes in response to Rv2628- and RD1-antigens in active TB and LTBI
subjects. Response to Rv2628- (A) and RD1-antigens (B) in active TB patients; response to Rv2628- (C) and RD1-antigens (D) in LTBI subjects.
Footnote: PBMC: peripheral blood mononuclear cells; BALC: bronchoalveolar lavage cells; SFC: spot-forming cells; IFN: interferon; TB: tuberculosis;
LTBI: latent TB infection. Dotted lines link the results obtained for circulating and local lymphocytes for the same patient.
doi:10.1371/journal.pone.0027539.g001
Figure 2. Magnitude of RD1-response is significantly higher than Rv2628-response in PBMC and BALC, evaluated by ELISPOT.
ELISPOT evaluation of IFN-c-producing CD4
+ T-cells in PBMC and BALC in response to Rv2628- and RD1-antigens in LTBI and active TB subjects.
Response to Rv2628- and RD1-antigens in PBMC of active TB and LTBI subjects (A), response to Rv2628- and RD1-antigens in BALC of LTBI and active
TB subjects (B) Footnote: PBMC: peripheral blood mononuclear cells; BALC: bronchoalveolar lavage cells; SFC: spot-forming cells; IFN: interferon; TB:
tuberculosis; LTBI: latent TB infection.
doi:10.1371/journal.pone.0027539.g002
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specific T-cells are EM. This result is important in light
of the reports performed in animal models. These reports
show that EM T-cells, following antigen presentation in the
local draining lymph nodes, migrate to the lung [35] and
become involved in local host defense against pathogens
through macrophage activation and neutrophil recruitment
[28,36].
Figure 3. Increased frequency of Rv2628- and RD1-response in BALC than PB in active TB, evaluated by FACS. FACS analysis of the
multiple cytokine producing CD4
+ T-cells (IFN-c and/or IL-2) in PB and BALC in response to Rv2628- (A) and RD1-antigens (B) stimulation in active TB
patients. Footnote: PB: whole blood; BALC: bronchoalveolar lavage cells. Dotted lines link the results obtained for circulating and local lymphocytes
for the same patient.
doi:10.1371/journal.pone.0027539.g003
Figure 4. Cytokine profile in response to Mtb-specific antigens in active TB. Polyfunctional cytokine production analysis of Mtb-specific
CD4
+ T-cells by FACS. PB and BALC from active TB patients were stimulated overnight with Rv2628- and RD1-antigens. T- cells were classified as single
IFN-c-producing, single IL-2-producing or double IFN-c/IL-2–producing cells in response to Rv2628- (A) and RD1-antigens (B). The results are reported
as relative median in PB compared to BALC samples (A–B). Black triangles: PB; open triangles: BALC. Footnote: PB: peripheral blood; BALC:
bronchoalveolar lavage cells; IFN: interferon; IL: interleukin.
doi:10.1371/journal.pone.0027539.g004
Rv2628 Response at the Site of Tuberculosis
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relatively small number of subjects, especially for the LTBI group.
Given the appreciable risk associated with bronchoscopy, our
institute only provides this procedure for those individuals with a
high suspicion of active TB and who result negative to AFB smear
in the sputa. Although larger sample sizes with consequently
longer time periods for enrolment would have probably increased
the total number of individuals with LTBI, antigen-specific T-cell
frequencies in BAL samples would likely be low in general [23,24],
and therefore preclude a large scale analysis of cytokine profiles
and T-cell phenotypes in individuals with latent infection.
Moreover, in active TB, both patients with microbiological and
clinical diagnosis were included without distinct subgroup analysis.
However, the results among the two subgroups were comparable
(data not shown) and consequently combined. Despite these
limitations, this study is unique because for the first time it
provides information regarding the response to the antigens of
latency at the site of Mtb infection, and their phenotypic
characterization.
In summary, our results indicate that there is a high frequency
of specific T-cells to both secreted (RD1) and latency-associated
(Rv2628) antigens in the BAL of patients with active TB and that
the majority of IFN-c-only secreting T-specific cells in BALC have
an EM phenotype. In light of the fact that not all lesions in the
human lung are active during the disease [2,4] and that
consequently Mtb infection may be viewed as a continuous
spectrum extending from sterilizing immunity to fulminant TB
[2,4] these data may be important for better understanding the
pathogenesis of TB in the lung.
Materials and Methods
Ethics Statement
This study was approved by the Ethical Committee of our
institution, the L. Spallanzani National Institute of Infectious
diseases (INMI), approval number 70/2005. Informed written
consent, required in order to participate in the study, was
obtained.
Patients
Patients admitted to INMI between 2009 and 2010 because of a
clinical suspicion of TB were considered for enrollment in this
study. According to the institutional protocol (http://www.inmi.
it/protocolli) BAL is indicated for TB suspects if 3 expectorated or
2 induced-sputa result AFB smear negative and no alternative
diagnosis is performed. TB suspects were enrolled in the study if: i)
they underwent BAL as part of the confirmatory procedure for TB
diagnosis, ii) they provided signed informed consent, iii) at least
6610
6 mononuclear cells from BAL could be recovered, iv) they
tested negative for HIV and were not undergoing treatment with
immunosuppressive drugs.
BAL was performed by instilling a sterile isotonic saline solution
(4 times 30 ml) into an affected lung segment.
Active TB was defined as microbiologically confirmed if the
BAL resulted Mtb culture-positive. Patients who resulted negative
to Mtb culture in BAL were classified as having ‘‘clinical TB’’ when
i) clinical, pathological and radiological findings consistent with
TB were documented; ii) an alternative diagnosis was excluded,
and iii) a full course of anti-TB treatment was started and an
appropriate clinical/radiological response was obtained.
Patients with lung diseases other than TB had a final diagnosis
made based on microbiological and cytological tests, clinical and
radiological signs, and successful treatment.
Blood and BAL Processing
Heparinized PB was collected and processed within 2 hours.
PBMC were isolated by standard methods on Ficoll-Paque Plus
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden) [21]. BALC
were obtained by passing the fluid through a sterile cell strainer
with a pore size of 100 mm (BD Becton, Dickinson and Company,
Milan, Italy) and then washing them with PBS.
QuantiFERON TB-Gold In tube (QFT-IT)
QFT-IT (Cellestis Limited, Carnegie, Victoria, Australia) was
performed. Results were scored as indicated by the manufacturer.
IFN-c ELISPOT
250,000 BALC or PBMC were stimulated with Rv2628 latency
antigen at 10 mg/ml and RD1-antigen at 4 mg/ml or with the
mitogen (positive control) (from the T-SPOT.TB, Oxford
Immunotec Ltd., Abingdon, UK following the manufacturer’s
instructions). Unstimulated sample (negative control) was included.
ELISPOT results for Rv2628- and RD1-stimulations were scored
as positive if more than 7 SFC/well were counted in the stimulated
wells after subtracting the number of SFC in the negative control.
ELISPOT results were scored as i) negative if they did not meet
the definition for a positive result, ii) indeterminate if more than
10 SFC/well in the negative control were counted and iii) anergic
if less than 20 SFC/well were counted in the positive control.
Intra-cellular staining (ICS)
PB (100 ml) and BALC (10
6) were stimulated overnight at 37uC
in 5% CO2 with recombinant Mtb-specific antigens [37] identified
Figure 5. Phenotype profile in response to Mtb-specific antigens in active TB. Phenotypical T-cell subset distribution of the total cytokine-
producing T-cells in response to Rv2628- (A) or RD1-antigens (B) are reported in PB and BALC samples. Footnote: PB: peripheral blood; BALC:
bronchoalveolar lavage cells; N: naı ¨ve; CM: central memory; EM: effector memory; EF: terminally
-differentiated effector memory.
doi:10.1371/journal.pone.0027539.g005
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Germany) at 4 mg/ml, respectively. Phorbol-12-myristate-13-
acetate (PMA) at 3 nM (SERVA Electrophoresis GmbH, Heidel-
berg, Germany) plus ionomycin at 1.5 mM (SERVA) was used as
positive control. Cells were co-stimulated with anti-CD28 and
anti-CD49d monoclonal antibodies (MoAb) at 2 mg/ml each (BD).
Unstimulated PB and BALC were used to assess non-specific
background cytokine production. Brefeldin A (SERVA) at 50 mg/
ml was added after 1 hour of stimulation.
ICS was performed to measure IFN-c and IL-2 production by
CD4
+ or CD8
+ T-cells upon in vitro stimulation. PB and BALC
were harvested, washed in PBS containing 1% BSA and 0.1%
sodium azide (NaN3), and then stained with monoclonal
antibodies (MoAb) directly conjugated to fluorochromes: allophy-
cocyanin (APC)-H7-conjugated anti-CD4; peridinin chlorophyll-
protein (PerCP)-Cy5.5-conjugated anti-CD8; phycoerythrin (PE)-
Cy7-conjugated anti-CD45RO, and allophycocyanin (APC)-
conjugated anti-CD62L (all from BD) in an incubation buffer
(PBS-1% BSA-0.1% NaN3) for 30 min at 4uC. Subsequently, PB
and BALC were washed, permeabilized with PBS-1% BSA-0.5%
saponin-0.1% NaN3 and stained for 15 min at RT for intracellular
cytokines with fluorescein isothiocyanate (FITC)-conjugated anti-
IFN-c and anti-IL-2-PE, or isotype-matched control MoAb (all
from BD). Cells were washed, fixed in 2% paraformaldehyde, and
at least 100,000 lymphocytes were acquired using a FACSCanto II
flow cytometer (BD Biosciences), following gating according to
forward and side scatter plots. FACS plots were analyzed using BD
FACSDiva software (version 6.1.1). Frequencies of the different
combinations of IFN-c and/or IL-2 -positive cells following
antigenic stimulation were calculated within the total population of
CD4
+ T-cells, and background values (unstimulated sample) were
subtracted. Values corresponding to spontaneous IFN-c and IL-2
production in the absence of in vitro stimulation were subtracted
from the values obtained after antigen stimulation. At least 30,000
CD4
+ T cells were analyzed. We established the lowest limit of
detection for performing the analysis at 0.06% in order to have at
least 18 events to analyze. FACS results were considered anergic if
unresponsive to the positive control.
Statistical analysis
Data were analyzed by the GraphPad Prism software, version
4.00 for Windows (GraphPad Software, San Diego, CA, USA).
For continuous measures, medians and IQR were calculated. The
significance of the differences between the two groups was
determined using the non-parametric Mann-Whitney test or the
Willcoxon test, when paired values were compared. Kruskall
Wallis was used to compare medians among the different groups.
For dichotomous measures, chi square was used. Differences were
considered significant at p values #0.05.
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